Menlo Therapeutics Inc. (NASDAQ: MNLO) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On December 10, 2018, Menlo Therapeutics Inc. issued a press release announcing the results of its Phase 2 clinical trial of serlopitant for the treatment of psoriasis. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Security Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Menlo Therapeutics Inc. Exhibit
EX-99.1 2 mnlo-ex991_6.htm EX-99.1 mnlo-ex991_6.htm Exhibit 99.1   Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis   Company to Conduct Conference Call and Webcast Today at 8:00am ET / 5:00am PT   REDWOOD CITY,…
To view the full exhibit click here